AstraZeneca PLC (AZN)vsPulsenmore Ltd. Ordinary Shares (PLSM)
AZN
AstraZeneca PLC
$161.42
+0.88%
HEALTHCARE · Cap: $263.09B
PLSM
Pulsenmore Ltd. Ordinary Shares
$3.31
-3.50%
HEALTHCARE · Cap: $22.17M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.0% profit margin vs -39.6%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
PLSM
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$161.42
$35.51 discount
Intrinsic value data unavailable for PLSM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 578.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 0.0%
ROE of -31.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : PLSM
The strongest argument for PLSM centers on Revenue Growth, Debt/Equity. Revenue growth of 578.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : PLSM
The primary concerns for PLSM are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while PLSM is a hypergrowth play — different risk/reward profiles.
PLSM carries more volatility with a beta of 0.38 — expect wider price swings.
PLSM is growing revenue faster at 578.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 39/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Pulsenmore Ltd. Ordinary Shares
HEALTHCARE · MEDICAL DEVICES · USA
Pulsenmore Ltd. engages in the provision of self-scan ultrasound devices for remote clinical diagnosis and screening in Israel and Europe. The company is headquartered in Omer, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?